Pliant Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing medicines to treat fibrosis—the scarring that makes organs like the lungs and liver stiff. Pliant's name plays on its mission: its therapies aim to make rigid, scarred tissue "pliant," or flexible again. Founded in 2015 by researchers from the University of California, San Francisco, the company targets integrins, proteins that drive the scarring process, with drug candidates for fibrotic and cancer conditions.
Granted 366.3K · Sold 206.2K
Granted 154.2K · Sold 64.8K
Granted 91.0K · Sold 35.6K
Granted 112.6K · Sold 41.1K
Granted 81.5K · Sold 36.4K
Granted 51.9K · Sold 11.3K
Sold 6.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Coulie BernardPresident and CEO, Director · 7 transactions | +21.8% | 914.9K | 366.3K | — | 206.2K |
| Cummings Keith LamontChief Financial Officer · 8 transactions | +45.7% | 297.2K | 154.2K | — | 64.8K |
| Hull HansChief Business Officer · 6 transactions | +14.7% | 287.3Kas of Jan 2025 | 91.0K | — | 35.6K |
| Lefebvre EricChief Medical Officer · 6 transactions | +43.7% | 240.2Kas of Jan 2025 | 112.6K | — | 41.1K |
| Ouimette MikeGeneral Counsel & Corp. Sec'y · 7 transactions | +74.6% | 105.5Kas of Jan 2025 | 81.5K | — | 36.4K |
| Cheung LilyChief Human Resource Officer · 4 transactions | — | 44.8K | 51.9K | — | 11.3K |
| Kuo MinnieChief Operating Officer · 1 transaction | — | 37.8K | — | — | 6.9K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -402.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.